ImetelChat

I think it is a standard disclaimer. For MF we know a lot about potential toxicities and side effects. There has been quite some official reporting about that, e.g. from Dr.T. So no need for Dr.S. to repeat this again. For MDS there is less known/published about toxicities. That could explain the di...

Scott: it was not written in stone, but mentioned by Dr.S in the latest telco.

Bp: Please let them go straight forward with the current single drug trials. All the comboing after approval... I am not sure I understand your concern.

Bp, anemia is a symptom. If severe, it may not be possible to use imetelstat due to myelosuppression. So if luspatercept is capable of reduce anemia, imetelstat may be administered. You see this now with the combination EPO and interferon in MF. Anemic patients will have problems with interferon due...

Slide 25: AML still in there as a phase 2/3 trial.

Having said that, the opening statement on slide 3 about imet directly attacking the malignant progenitor cells, is a strong claim, for which they must have seen quite some evidence. Slides 5 and 7 suggest that imet may target hematologic malignancies, which are a broad set of indications. Slide 9 p...

Not much new on it...Q2 2017 seems to be the moment of truth.

Happy New Year to you all!

Bio/Scott: thanks for posting this interesting article. I will upload it to imetelstat.info

Hi Sargasso, these are all very good questions. It seems JnJ/Geron chose the MF R/R because no alternative exists as you say. That means that any positive result on these patients will be a 'victory' on BAT. I think JnJ/Geron will also look to the kind and depth of the response, in addition to the s...

Bio, thanks for your kind and motivating words. Your contributions , and those of other members on this board are highly appreciated. I hope we can keep the good discussion and reflections going for 2017. I will do my best to keep facilitating it.

I wish all of you a happy and healthy 2017!

Bio, legally you are probably right. On the other hand, I consider it as material information, so... maybe I'll drop a line to Geron and ask Anna directly. Who knows we'll get some answer. Nice predictions. Could all happen as you say. Not too sure about the acquisition though, probably too early. G...

I guess he has to, indeed.

From Ligas on SA: "I really don't think they will make any decisions until all patients in the study have reached 24 weeks. Remember that according to response criteria, any response must be held for 12 weeks at least to be considered a response considering all of the first 20 were at 12 weeks in Se...

From Bio on SA: "I have thought about your comments and I may be incorrect as you suggest in my timing, if so I apologize and did not intend to be misleading. My understanding is that as each patient reaches first the 12 week mark, and then the 24 week mark they are analyzed on a rolling basis, that...

From Ligas3 on SA: "I saw your post about the 24 week analysis. Your time frames are wrong. The 12 week analysis of the first 20 patients is completely separate from the 24 week analysis of all patients in the study, emphasize all. If 20 patients were at 12 weeks in September then they certainly wou...

Bio, your observation that we have an omission here regrading the provision of material information is a serious matter. I would suggest to send an email to Dr.S. He probably knows you and will likely read your email. I believe he shouldn't leave such an email unanswered.

Aha! I didn't make the connection. No it is clear. Tx

Hi, Bio. Thanks for your post. It keeps a matter of guessing, because we don't know what is going behind the scenes. The AML and CML presentations at ASH are intriguing and suggest a direction JnJ is looking at next to MDS and MF. On the other hand, there may be plans in a total other direction whic...

Although this latest patent is too technical for me to really understand, herewith a note on the general importance the proper management of IP by Geron: From the 10-K (over 2015) We remain responsible for prosecuting, at Janssen's direction, the patents we have exclusively licensed to Janssen. The ...

People who wish to register as a member to ImetelChat need to wait until 9 January 2017. Due to holidays the registration facility will be closed until that date. Existing members can log in and keep posting as usual.

Have a nice Xmas!

Admin

USPTO Applicaton #: #20160362440 Applicant: Geron Corporation Inventors: Sergei M. Gryaznov, Krisztina Pongracz, Daria Zielinska Date: 12/15/16 Abstract Orthogonally protected 3′-amino nucleoside monomers and efficient methods for their synthesis are described. The methods employ selective protectio...